Adrenaline, articaine
Sold as Ubistesin, Ubistesin forte
Every registration of this product has been cancelled.
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
Drag to rotate. Structure from PubChem CID 5816.
Background
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| 3m South Africa (Pty) LtdCancelled | Ubistesin, Ubistesin forte | Not stated | A380430, A380431 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ubistesin Each 1,0 ml Solution Contains:Articaine Hydrochloride 40,0 mg, Adrenaline Hydrochloride Equivalent to Adrenaline 0,05 mg | Not listed | A380430 | Cancelled | Not determined | None |
| Ubistesin forte Each 1,0 ml Solution Contains:Articaine Hydrochloride 40,0 mg, Adrenaline Hydrochloride Equivalent to Adrenaline 0,01 mg | Not listed | A380431A38/4/0431 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Adrenaline
- when intended for injection.
Consolidated Schedules 06 July 2026, line 5148
S3: Adrenaline
- ophthalmic preparations thereof, when intended for glaucoma.
Consolidated Schedules 06 July 2026, line 3122
S2: Adrenaline
- ophthalmic preparations when intended for glaucoma, and
- preparations for injection. (S3, S4)
Consolidated Schedules 06 July 2026, lines 1561 to 1565
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.